Nexus Pharmaceuticals Email Format
Pharmaceutical ManufacturingIllinois, United States51-200 Employees
Nexus Pharmaceuticals operates in the pharmaceutical manufacturing sector from a base in Lincolnshire, Illinois. It is a US-based, family- and minority-owned healthcare company. It pursues innovative production methods designed to simplify the manufacture of hard-to-produce specialty drugs, making them easier to administer and less labor-intensive in practice. The firm emphasizes that its FDA-approved medicines aim to address unmet medical needs and be available when patients need them most. The company expanded its injectable portfolio with launches in 2025, including Methylene Blue Injection and Tranexamic Acid, and added Cyclophosphamide Injection in 2026. In 2025, Ingenus Pharmaceuticals filed a lawsuit alleging infringement of a cyclophosphamide-related patent.